VMT-𝛼-NET / Perspective Therap, Lantheus - LARVOL DELTA

[212Pb]VMT-α-NET therapy in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs): Dose-limiting toxicity (DLT) observation participants after 1 year follow-up and preliminary report for expansion participants. (ASCO 2025) - P1/2 | "[212Pb]VMT-α-NET is a well-tolerated, next generation RPT showing signs of clinical activity at early dose-levels in this phase 1/2a study. Based on these clinical data, further dose-escalation and development of this promising therapy are warranted."

Endocrine Cancer • Gastrointestinal Disorder • Nephrology • Neuroendocrine Tumor • Oncology • Renal Disease • Solid Tumor • SSTR • SSTR2

A Phase 0 Imaging Trial of [203Pb]Pb-VMT-α-NET to Enable Dosimetry and Treatment Planning for Refractory or Relapsed Metastatic Neuroendocrine Tumors with [212Pb]Pb-VMT-α-NET. (PubMed, J Nucl Med) - " [203Pb]Pb-VMT-α-NET appears to be a safe and effective SPECT/CT tracer for imaging NETs larger than 1 cm and for normal organ and tumor radiation dosimetry. The chemically matched 203/212Pb theranostic pair offers the potential for a dosimetry-driven personalized treatment paradigm."

Journal • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR • SSTR2

[212Pb]VMT-α-NET targeted alpha-particle therapy (TAT) for advanced somatostatin receptor 2-positive (SSTR2+) neuroendocrine tumours (NETs): Mature safety and preliminary efficacy for enrollment from dose-finding cohorts 1 and 2 (n=44) (ESMO 2025) - P1/2 | "Conclusions [ 212 Pb]VMT-α-NET is a well-tolerated, novel, next-generation TAT that demonstrates noteworthy clinical activity at the 185 MBq (5 mCi) dose level. These data justify further clinical development of this promising therapy."

Clinical • Metastases • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR • SSTR2

[212Pb]VMT-a-NET in advanced SSTR2+ neuroendocrine tumors: safety and preliminary efficacy results from dose-finding cohorts 1,2 and 3 (AACR 2026) - "Abstract is embargoed at this time."

Clinical • Metastases • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR2

Safety and preliminary efficacy results of [212Pb]VMT-a-NET in advanced somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors (NETs). (ASCO-GI 2026) - P1/2 | "[212Pb]VMT-a-NET showed a favorable safety profile and promising clinical benefit for patients with advanced SSTR2-expressing NETs treated at the dose levels of 92.5 MBq and 185 MBq. The study is ongoing with Cohort 3 (222 MBq) currently open for enrollment."

Clinical • Metastases • Gastrointestinal Cancer • Oncology • Solid Tumor • SSTR • SSTR2

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire) - "Updated efficacy analysis suggests durable disease control and deepening of tumor response per RECIST v1.1 in the first 23 patients in Cohort 2 and both patients in Cohort 1; Objective response in 39% of patients in Cohort 2 regardless of SSTR2 expression profile, including one Cohort 2 patient who experienced an initial objective response pending confirmation since the prior update, and 8 previously reported confirmed responders; Cohort 3 (6.0 mCi) dose limiting toxicities (DLT) assessment completed as planned; cleared to treat more patients with one additional patient already treated."

P1/2 data • Neuroendocrine Tumor

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)

P1/2 data • Neuroendocrine Tumor

Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors. (PubMed, Pharmaceuticals (Basel)) - "Early results support α-PRRT as a potential first- or second-line therapeutic option. Ongoing phase III trials will be critical to confirm its long-term safety, survival outcomes, and role in routine clinical practice."

Journal • Review • Gastrointestinal Disorder • Hematological Disorders • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR

Clinical Highlights: VMT-α-NET (GlobeNewswire) - "Among the 16 patients with SSTR2 expression in all of their tumors, seven (44%) achieved confirmed responses, and 14 (87.5%) remained progression-free and on study, with a median follow-up of 41 weeks. Initial anti-tumor activity data for an additional 23 patients in Cohort 2 and eight patients in Cohort 3 are expected to be submitted for presentation at a future medical conference in 2026."

P1/2 data • Neuroendocrine Tumor • Pancreatic Cancer • Paraganglioma • Pheochromocytoma

[212Pb]VMT-a-NET for somatostatin receptor subtype 2 (SSTR2)-expressing tumors: safety and preliminary efficacy results in patients with advanced neuroendocrine tumors (NETs) (AACR-NCI-EORTC 2025) - P1/2 | "[212Pb]VMT-a-NET showed a favorable safety profile and promising clinical benefit for patients with advanced SSTR2-expressing NETs treated at the dose level of 185 MBq (5 mCi). The study is ongoing with cohort 3 currently open for enrollment."

Clinical • Metastases • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR • SSTR2

[212Pb]VMT-alpha-NET for advanced SSTR+ NETs: safety and preliminary efficacy results from cohorts 1 and 2 of the dose escalation phase (NANETS 2025) - P1/2 | "CONCLUSIONS [212Pb]VMT-alpha-NET is a well-tolerated therapy for patients with advanced NETs, and it has shown promising clinical benefit at the dose level of 185 MBq [5 mCi]. The study is ongoing and open for enrollment in cohort 3."

Clinical • Metastases • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR • SSTR2

Perspective Therapeutics Provides Recent Business Highlights… (GlobeNewswire) - "Four of the initial seven patients enrolled in Cohort 2 experienced objective responses as defined by RECIST v1.1. Three of those patients experienced confirmed response and remained in response. One new first response was subject to confirmation. Seven of nine patients in Cohorts 1 and 2 remained free from disease progression after more than one year of follow-up."

P1/2 data • Neuroendocrine Tumor

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting

Enrollment open • Genito-urinary Cancer • Head and Neck Cancer • Kidney Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor

Perspective Therapeutics Provides Recent Business Highlights… (GlobeNewswire) - "Reached alignment with FDA in June to open Cohort 3 (6.0 mCi) of the [²¹²Pb]VMT-α-NET study. Two patients dosed in Cohort 3 as of July 31, 2025. An update of our [²¹²Pb]VMT-α-NET study accepted for presentation at the European Society of Medical Oncology Congress 2025 on October 20, 2025."

P1/2 data • Trial status • Neuroendocrine Tumor • Paraganglioma • Pheochromocytoma • Small Cell Lung Cancer

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Yusuf Menda | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Sep 2025 ➔ Apr 2026 | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Trial completion date • Trial primary completion date • Neuroendocrine Tumor • Solid Tumor • SSTR

[212Pb]Pb-VMT-α-NET dosimetry in patients with advanced SSTR2-positive tumors in the VMT-α-NET-T101 trial (SNMMI 2025) - P1/2 | "Theranostic investigations with [203Pb]Pb-VMT-α-NET provide an accurate and reliable means to predict dosimetry for alpha-particle RPT with [212Pb]Pb-VMT-α-NET. Dosimetric analysis of VMT-α-NET-T101 multi-timepoint imaging with [203Pb]Pb-VMT-α-NET in the screening stage of the trial demonstrates that [212Pb]Pb-VMT-α-NET has a favorable ratio of absorbed dose in tumors relative to kidneys. Additional comprehensive dosimetry analyses for sub-study patients will be presented at the congress."

Clinical • Metastases • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR • SSTR2

[212Pb]Pb-VMT-α-NET dosimetry in patients with advanced SSTR2-positive tumors in the VMT-α-NET-T101 trial (SNMMI 2025) - P1/2 | "Theranostic investigations with [203Pb]Pb-VMT-α-NET provide an accurate and reliable means to predict dosimetry for alpha-particle RPT with [212Pb]Pb-VMT-α-NET. Dosimetric analysis of VMT-α-NET-T101 multi-timepoint imaging with [203Pb]Pb-VMT-α-NET in the screening stage of the trial demonstrates that [212Pb]Pb-VMT-α-NET has a favorable ratio of absorbed dose in tumors relative to kidneys. Additional comprehensive dosimetry analyses for sub-study patients will be presented at the congress."

Clinical • Metastases • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR • SSTR2

177Lu-DOTATATE (LUMOD) and 212Pb-VMT-alpha-NET Trials at University of Iowa (SNMMI 2025) - "Sponsored by Dosimetry Task Force"

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting (GlobeNewswire) - "Perspective Therapeutics, Inc...today announced that data on the Company’s [212Pb]VMT-α-NET and [212Pb]VMT01 programs have been accepted for presentation as detailed below at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3, 2025 in Chicago, Illinois. ASCO plans to release further details for regular abstracts on May 22, 2025 at 5:00 PM EDT."

Clinical data • Melanoma

[203/212Pb]Pb-VMT-α-NET as a novel theranostic agent for targeted alpha radiotherapy-first clinical experience. (PubMed, Eur J Nucl Med Mol Imaging) - "Imaging with [203Pb]Pb-VMT-α-NET followed by a single dose of [212Pb]Pb-VMT-α-NET appears to be well tolerated with promising efficacy, even in a heterogenous and heavily pretreated patient population. Further studies are warranted to examine tolerability and efficacy over multiple treatment cycles in larger patient populations."

Journal • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR2

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results (GlobeNewswire) - "Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET....Since the start of 2025 through the end of February 2025, an incremental 12 patients have been dosed. Thus, a total of 30 patients have received treatment in Cohort 2 as of February 28, 2025. Cohort 2 remains open for recruitment. By 3Q and 4Q 2025, all patients enrolled through February 28, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol. We plan to submit to scientific congresses updates on patients dosed to date who have had the opportunity to receive at least one scan after their full treatment, in the second half of 2025."

Trial status • Neuroendocrine Carcinoma

Nuclear medicine and perspective thoughts in the diagnosis and treatment of pheochromocytoma and paraganglioma. (PubMed, J Neuroendocrinol) - "It also provides insight into the use of proliferating cell nuclear antigen (PCNA) inhibitors in combination with therapeutics in aggressive/metastatic PPGL. Through a comprehensive review of the latest developments and clinical practice, this review aims to guide healthcare professionals in improving the diagnostic accuracy and therapeutic efficacy of PPGL."

Journal • Review • CNS Tumor • Endocrine Cancer • Oncology • Solid Tumor • PCNA

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy (clinicaltrials.gov) - P1/2 | N=66 | Recruiting | Sponsor: National Cancer Institute (NCI) | Suspended ➔ Recruiting

Enrollment open • CNS Tumor • Endocrine Cancer • Gastrointestinal Disorder • Neuroendocrine Tumor • Oncology • Solid Tumor

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy (clinicaltrials.gov) - P1/2 | N=66 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Tumor • Endocrine Cancer • Gastrointestinal Disorder • Neuroendocrine Tumor • Oncology • Solid Tumor

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy (clinicaltrials.gov) - P1/2 | N=66 | Suspended | Sponsor: National Cancer Institute (NCI) | Recruiting ➔ Suspended

Trial suspension • CNS Tumor • Endocrine Cancer • Gastrointestinal Disorder • Neuroendocrine Tumor • Oncology • Solid Tumor